DualityBio Initiates Global Phase Ia/Ib Study of ADAM9‑Targeting ADC DB‑1317
Drug

DualityBio Initiates Global Phase Ia/Ib Study of ADAM9‑Targeting ADC DB‑1317

Trump Administration Expands Section 232 Tariffs on Robotics, Industrial Machinery and Medical Devices
CompanyMedical Device

Trump Administration Expands Section 232 Tariffs on Robotics, Industrial Machinery and Medical Devices

Hengrui Pharma & Glenmark Partner on Trastuzumab Rezecan ADC for HER2‑Positive Lung Cancer
CompanyDeals

Hengrui Pharma & Glenmark Partner on Trastuzumab Rezecan ADC for HER2‑Positive Lung Cancer

Jiangsu Hengrui Receives NMPA Acceptance for SHR7280 Oral GnRH Antagonist
CompanyDrug

Jiangsu Hengrui Receives NMPA Acceptance for SHR7280 Oral GnRH Antagonist

Johnson & Johnson Announces International Withdrawal of Linx Reflux System
CompanyMedical Device

Johnson & Johnson Announces International Withdrawal of Linx Reflux System

RM Bio‑Tech Secures CDE Approval for HF001 Stem‑Cell Therapy in Type 2 Diabetes
CompanyDrug

RM Bio‑Tech Secures CDE Approval for HF001 Stem‑Cell Therapy in Type 2 Diabetes

Jiangsu Hengrui’s Adebrelimab New Indication Accepted by NMPA for Stage II‑IIIB NSCLC
CompanyDrug

Jiangsu Hengrui’s Adebrelimab New Indication Accepted by NMPA for Stage II‑IIIB NSCLC

Yantai Dongcheng Secures NMPA Approval for 225Ac‑LNC1011 Alpha‑Particle Radiopharmaceutical to Target Prostate Cancer
CompanyDrug

Yantai Dongcheng Secures NMPA Approval for 225Ac‑LNC1011 Alpha‑Particle Radiopharmaceutical to Target Prostate Cancer

Eli Lilly Announces $6.5 B Houston Facility to Boost Synthetic‑Medicine API Production
Company

Eli Lilly Announces $6.5 B Houston Facility to Boost Synthetic‑Medicine API Production

Sino Biopharmaceutical Reports First‑Patient Enrollment for LM‑2417 Phase I Trial
CompanyDrug

Sino Biopharmaceutical Reports First‑Patient Enrollment for LM‑2417 Phase I Trial

MSD Teams with Variational AI in $349 Million Generative‑AI Drug Discovery Deal
CompanyDeals

MSD Teams with Variational AI in $349 Million Generative‑AI Drug Discovery Deal

ProBio and Immunofoco Forge Global CGT Manufacturing Alliance
CompanyDeals

ProBio and Immunofoco Forge Global CGT Manufacturing Alliance